✦ LIBER ✦

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

✍ Scribed by Didier Bouscary; Laurence Legros; Micheline Tulliez; Stéphanie Dubois; Béatrice Mahe; Odile Beyne-Rauzy; Marie C. Quarre; Dominique Vassilief; Bruno Varet; Achille Aouba; Martine Gardembas; Stéphane Giraudier; Agnès Guerci; Philippe Rousselot; Fanny Gaillard; Anne Moreau; Marie C. Rousselet; Norbert Ifrah; Pierre Fenaux; François Dreyfus; For The Groupe Français des Myélodysplasies (GFM)

Book ID: 108673500
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 383 KB
Volume: 131
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2005.05817.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib combined with low-dose cytara

Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM

✍ Shanti Natarajan-Amé; Sophie Park; Lionel Ades; Norbert Vey; Agnès Guerci-Bresle 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

High-dose darbepoetin alpha in the treat

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

✍ L. Mannone; C. Gardin; M. C. Quarre; J. F. Bernard; D. Vassilieff; L. Ades; S. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB